High-Dose Intravenous Immunoglobulin in the Management of Myasthenia Gravis

Archives of Internal Medicine

Volumn 146, Issue 7, 1986, Pages 1365-1368

  Arsura, Edward L ^a   Bick, Aaron ^a   Brunner, Norman G ^a   Namba, Tatsuji ^a   Grob, David ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR; CODEINE SULFATE; DIURETIC AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NEOSTIGMINE METHYL SULFATE; PARACETAMOL; PREDNISONE; PYRIDOSTIGMINE;

ADVERSE DRUG REACTION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG THERAPY; EDEMA; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE; MUSCLE STRENGTH; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; THERAPY;

ADULT; AGED; AUTOANTIBODIES; BLOOD PROTEINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISONE; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, CHOLINERGIC; THYMECTOMY; THYMOMA; THYMUS NEOPLASMS; TIME FACTORS; VITAL CAPACITY;

EID: 84941826680     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1986.00360190143020     Document Type: Article

References (30)

1. Grob D: Myasthenia gravis: A review of pathogenesis and treatment. Arch Intern Med 1961;108:615-638.
2. Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor. Science 1973;180:871-872.
3. Brunner NG, Namba T, Grob D: Corticosteroids in management of severe, generalized myasthenia gravis. Neurology 1972;22:603-610.
4. Brunner NG, Berger CL, Namba T, et al: Corticotropin and corticosteroids in generalized myasthenia gravis: Comparative studies and role in management. Ann NY Acad Sci 1976;274:577-595.
5. Arsura EL, Brunner NG, Namba T, et al: High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985;42:1149-1153.
6. Olarte MR, Schoenfeldt RS, Penn AS, et al: Effects of plasmapheresis in myasthenia gravis 1978-1980. Ann NY Acad Sci 1981;377:725-728.
7. Howard JF: Nonsteroidal immunosuppressive therapy for myasthenia gravis. Semin Neurol 1982;2:265-269.
8. Papatestas AE, Genkins G, Kornfeld P: Comparison of the results of the transcervical and transsternal thymectomy in myasthenia gravis. Ann NY Acad Sci 1981;377:766-778.
9. Grob D, Brunner NG, Namba T: The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 1981;377: 652-669.
10. Imbach P, d’Apuzzo V, Hirt A, et al: High-dose intravenous gammaglobulin per idiopathic thrombocytopenic purpura in childhood. Lancet 1981;2:475-476.
11. Fehr J, Hofmann V, Kappiler V: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982;306:1254-1258.
12. Pollack S, Cunningham-Rundles C, Smithwick EM, et al: High-dose intravenous gammaglobulin for autoimmune neutropenia. N Engl J Med 1982;307:253.
13. Sultan Y, Kazatchkine MD, Maisonneuve P, et al: Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984;2:765-767.
14. Furusho K, Tetsuro K, Hiroyaki N, et al: High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-1057.
15. Fateh-Moghadam A, Besinger U, Guersen RG: Ein klinisches Modellzur Regulation der humoralen Immunawort: Infusion Therapie. Beitr Infusionther Klinis Ernahr 1982;9:69-79.
16. Gajdos PH, Outin H, Elkharrat D, et al: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1:406-407.
17. Fateh-Moghadam A, Wick M, Besinger U, et al: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1:848-849.
18. Ippoliti G, Cosi V, Piccolo G, et al: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;2:809.
19. Devathason G, Kueh YK, Chong PN: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;2:809-810.
20. Genkins G, Horowitz SH, Kornfeld P, et al: Studies in myasthenia gravis: Gammaglobulins and staging. Read before the Scientific Session of the Myasthenia Gravis Foundation, New York, 1976.
21. Lindstrom J, Seybold ME, Lennon VA, et al: Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates and diagnostic value. Neurology 1976;26:1054-1059.
22. Pascuzzi RM, Coslett HB, Johns TR: Myasthenia gravis treatment with long-term corticosteroids: A report of 116 cases. Ann Neurol 1984;15: 291-298.
23. Cunningham-Rundles C, Siegel FP, Smithwick EM, et al: Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984;101:435-439.
24. Lever A, Webster A, Brown D, et al: Non-A non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984;2:1062-1064.
25. Bussel JB, Kimberly RP, Inman RD: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983;62: 480-486.
26. Ragsdale CG, Arend WP: Loss of Fc receptor activity after culture of human monocytes on surface-bound immune complexes. J Exp Med 1980;151:32-49.
27. Bartoloni C, Guidi L, Scoppetta C, et al: Circulating immune complexes in myasthenia gravis: A study in relation to thymectomy, clinical severity and thymus histology. J Neurol Neurosurg Psychiatry 1981;44: 901-905.
28. Engel AG, Sakakibara H, Sahashik K, et al: Passively transferred experimental autoimmune myasthenia gravis: Sequential and quantitative study of endplate localization of immune complexes (IgG and C3) and of acetylcholine receptor. Neurology 1979;29:179-188.
29. Drachman DB: Myasthenia gravis (first of two parts). N Engl J Med 1978;298:136-142.
30. Drachman DB, Angus WC, Adams RN, et al: Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978;298:116-122.